Skip to main content
. 2021 Aug 14;21:920. doi: 10.1186/s12885-021-08656-0

Fig. 4.

Fig. 4

Subgroup analysis for DFS and OS according to the TGIF immunostaining (moderate/strong vs negative/low) with regards to treatment arm (iddEPC and ddEC-PwX): A DFS iddEPC treatment (HR 0.70 [95% CI 0.50–0.98]; log-rank p = 0.037). B OS iddEPC treatment (HR 0.69 [95% CI 0.45–1.07]; log-rank p = 0.096). C DFS iddEC-PwX treatment (HR 0.81 [95% CI 0.58–1.14]; log-rank p = 0.229). D OS iddEC-PwX treatment HR 0.69 [95% CI 0.45–1.08]; log-rank p = 0.106